Otis Webb Brawley
Independent DirectorDr. Otis Webb Brawley, MD, MACP, FASCO, FACE, FACP, is Member of Advisory Board of Cure Media Group, LLC. Dr. Brawley has been Member of Scientific Advisory Board at Syapse, Inc. since 2022. Dr. Brawley serves as Independent Director for Agilent Technologies, Inc. since November 17, 2021. He served as Member of Advisory Board at GRAIL LLC until 2024. He has served as Director at Incyte Corporation since September 27, 2021 and serves as its Independent Director. He served as an Independent Director of PDS Biotechnology Corporation November 3, 2020 until October 18, 2026. He serves as an Independent Director at Lyell Immunopharma, Inc. since April 2021. He is a renowned oncologist and a seasoned pharmaceutical director who has served on several boards including the boards of companies developing and commercializing oncology products. He was a Professor of Medicine, Hematology and Oncology at the Emory University School of Medicine since April 2001 until December 2018 and Professor of Epidemiology at the Emory University Rollins School of Public Health. Dr. Brawley serves as Chief of Hematology and Oncology Services and the Medical Director of the Georgia Cancer Coalition Center of Excellence at Gardy Memorial Hospital. He serves as Associate Director for Cancer Control of the Winship Cancer Institute of Emory University. He served as the Chief Medical and Scientific Officer at the American Cancer Society from April 2007 until December 2018. He serves as associate editor and reviewer for several prestigious scientific publications. Dr. Brawley served as a Senior Investigator and Assistant Director of the National Cancer Institute Board of Scientific Counselors. From January 2002 to August 2007, Dr. Brawley was director of the Georgia Cancer Center at Grady Memorial Hospital. He is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University since January 2019. He served as a Director of Theragenics Corp. from 1995 to January 1, 2008. He was an internist and oncologist at the National Institutes of Health Clinical Center and Bethesda Naval Hospital. He served as a Member of Clinical Advisory Board of Avalon Pharmaceuticals, Inc. since January 2007. He serves on several governmental scientific advisory boards and has designed a number of clinical trials. He is a board-Certified Medical Oncologist. In August 2001, Governor Roy Barnes named Dr. Brawley a Georgia Cancer Coalition Eminent Scholar. He has authored more than sixty peer-reviewed publications. He was also previously a senior investigator at the National Institute of Health (NIH) and NCI. In 2013, he was the recipient of a Special Recognition Award from the American Society of Clinical Oncology. Dr. Brawley is a Director at Jackson Laboratories, a nonprofit biomedical research center focused on developing genomic solutions to disease including personalized, tailored therapeutics for individual cancers; formerly, he was a Director for the Theragenics Corporation, a publicly traded company with commercialized medical devices for brachytherapy, surgery and wound closure. He is board certified in internal medicine and medical oncology. In 2019 he was given the American Medical Association Distinguished Service Award Dr. Brawley is an elected member of the National Academy of Medicine. He completed an internal medicine residency at Case-Western Reserve University and a fellowship in medical oncology at the NCI. He received his M.D. from the University of Chicago Pritzker School of Medicine and his B.S. in chemistry from the University of Chicago.
Positions
- Company NameLyell Immunopharma, Inc.Stock CodeLYELPositionIndependent DirectorColleagues
- RDRichard D. KlausnerFounder & Executive Chairman
- LSLynn SeelyPrincipal Executive Officer, President, CEO & Director
- SJStephen J. HillChief Operating Officer
- GKGary K. LeeChief Scientific Officer
- SRStanley R. RiddellFounder & Scientific Advisor
- CJCatherine J. FriedmanLead Independent Director
- WJWilliam JL RieflinIndependent Director
